Recombinant HSV-1 vector for coding immune stimulating factor and anti-immune checkpoint antibody
Patent Information
- Application Number
- CN202380033511.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-05-23
- Filing Date
- 2023-05-22
- Publication Date
- 2024-11-19
AI Technical Summary
Existing oncolytic viruses have problems with high side effects, poor safety, and limited therapeutic dosage in tumor treatment, resulting in limited clinical therapeutic effects and potential safety hazards.
The recombinant HSV-1 vector was constructed by genetically modifying the herpes simplex virus (HSV-1) to delete the ICP34.5 gene and insert exogenous nucleic acid sequences encoding immune stimulatory factors and anti-immune checkpoint antibodies between the UL26/27 genes. , to improve the anti-tumor effect and safety of the virus.
It achieves a high level of virus expression stability and anti-tumor activity, has better tumor-inhibitory effect than the unmodified virus, and shows significant killing ability on a variety of tumor cells.
Smart Images

Figure CN118984872A_ABST
Abstract
Description
A recombinant HSV-1 vector encoding immune stimulatory factors and anti-immune checkpoint antibodies Technical Field
[0001] The present disclosure relates to the fields of immunology and gene delivery. More specifically, the present application relates to a recombinant HSV-1 vector that carries and expresses immune stimulatory factors and anti-immune checkpoint antibodies. Background Art
[0002] Oncolytic viruses are genetically modified or naturally occurring viruses. They preferentially replicate and lyse cancer cells, inducing an anti-tumor immune response while sparing normal cells. Therefore, they represent a promising anti-tumor therapeutic approach. Currently, a variety of pathogens, including herpes simplex virus, adenovirus, poxvirus, and coxsackievirus, have been used in the preparation of oncolytic viruses.
[0003] Among them, herpes simplex virus has attracted much attention in the preparation of oncolytic viruses because it has the following advantages as an oncolytic virus vector: 1. The functions of the genome and viral gene products are clear; 2. The genome is large and can accommodate multiple exogenous genes; 3. There is no risk of viral genome integration; 4. The modification technology is mature; 5. The safety has been verified after administration to the human body; 6. It has strong immunogenicity.
[0004] Currently, oncolytic viruses can be divided into more than ten types according to the type of virus. Among them, the oncolytic herpes simplex virus type 1 (HSV-1) has become the first choice for genetically engineered tumor therapeutics at home and abroad because the viral vectors used have advantages such as large gene capacity, short replication cycle, high infection efficiency, and the ability to insert multiple therapeutic genes. However, since different oncolytic viruses have different genetic modifications, different oncolytic effects and safety, their applicable tumor indications and tumor treatment effects are also different (Eager RM, Nemunaitis J. Clinical development directions in oncolytic viral therapy [J]. Cancer Gene Ther, 2011, 18 (5): 305-317). Existing oncolytic viruses all have defects such as large toxic side effects, poor safety, and significantly limited therapeutic doses of oncolytic viruses, which poses a severe challenge to tumor treatment research (Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress [J]. Nat Clin Pract Oncol, 2007, 4 (2): 101-117). Due to the low specificity and safety of oncolytic viruses, in order to avoid causing serious side effects to the body, the dosage will be reduced. This will affect the clinical treatment effect of oncolytic viruses and lead to certain safety risks.
[0005] Currently, the anti-tumor immune effect induced by oncolytic herpes simplex virus (oHSV) can be enhanced by assembling anti-tumor immune regulatory factors. At the same time, anti-tumor immune regulatory factors can reverse the immunosuppressive effect of the tumor microenvironment, promote inflammatory cell infiltration, and enhance the anti-tumor effect of oncolytic viruses.
[0006] Therefore, there is still a need to develop new oncolytic viruses to achieve low toxicity and high efficacy of oncolytic virus therapy and to further enhance the anti-tumor effect by combining the expression of anti-tumor immune regulatory factors.
[0007] Summary of the Invention
[0008] The present disclosure provides a recombinant herpes simplex virus type 1 (hereinafter also referred to as HSV-1, HSV-1 virus or HSV-1 vector), comprising a modified HSV-1 genome, wherein the modification comprises a deletion of the ICP34.5 gene in the HSV1-KOS strain genome. Preferably, the modification results in the deletion of both copies of the ICP34.5 gene.
[0009] On the one hand, the present disclosure provides a recombinant HSV-1 vector comprising a modified HSV-1 genome, wherein the modification comprises a deletion of the ICP34.5 gene in the HSV1-KOS strain genome, and the vector comprises: (a) a first exogenous nucleic acid sequence encoding an immunostimulatory factor; (b) a second exogenous nucleic acid sequence encoding an anti-immune checkpoint antibody; wherein the first exogenous nucleic acid sequence or the second exogenous nucleic acid sequence is inserted between the UL26 and UL27 genes of the HSV1-KOS strain genome, and the insertion of the first exogenous nucleic acid sequence does not interfere with the expression of HSV-1. Preferably, the second exogenous nucleic acid sequence is inserted between the UL26 and UL27 genes of the HSV1-KOS strain genome, and the insertion of the second exogenous nucleic acid sequence does not interfere with the expression of HSV-1.
[0010] In some embodiments, the recombinant HSV-1 vector as described above, wherein the first exogenous nucleic acid sequence encoding an immunostimulatory factor is inserted into the region where the ICP34.5 gene is deleted in the HSV1-KOS strain genome or between the UL3 and UL4 genes of the HSV1-KOS strain genome, and the second exogenous nucleic acid sequence encoding an anti-immune checkpoint antibody is inserted between the UL26 and UL27 genes of the HSV1-KOS strain genome.
[0011] In some embodiments, the recombinant HSV-1 vector as described above, wherein the first exogenous nucleic acid sequence encoding an immunostimulatory factor is inserted between the UL26 and UL27 genes of the HSV1-KOS strain genome, and the second exogenous nucleic acid sequence encoding an anti-immune checkpoint antibody is inserted into the region where the ICP34.5 gene is deleted in the HSV1-KOS strain genome or between the UL3 and UL4 genes of the HSV1-KOS strain genome.
[0012] In some embodiments, the recombinant HSV-1 vector as described above, wherein the immunostimulatory factor is selected from at least one of GM-CSF, IL-2, IL-12, IL-15, IL-24 and IL-27; the immune checkpoint is selected from at least one of PD-1, CTLA-4, VISTA, LAG-3, TIGIT and PD-L1.
[0013] In some embodiments, the recombinant HSV-1 vector as described above, wherein the vector comprises: (a) a first exogenous nucleic acid sequence encoding IL-12; (b) a second exogenous nucleic acid sequence encoding an anti-PD-1 antibody; wherein the second exogenous nucleic acid sequence of the anti-PD-1 antibody is inserted between the UL26 and UL27 genes of the HSV1-KOS strain genome.
[0014] In some embodiments, the recombinant HSV-1 vector as described above, wherein the first exogenous nucleic acid sequence encoding IL-12 is inserted into the region where the ICP34.5 gene is deleted in the HSV1-KOS strain genome or between the UL3 and UL4 genes in the HSV1-KOS strain genome.
[0015] In some embodiments, in the recombinant HSV-1 vector as described above, the deletion of the ICP34.5 gene is a double copy deletion of the ICP34.5 gene or a deletion of amino acids 1-146 of the N-terminal sequence of the ICP34.5 gene.
[0016] In some embodiments, in the recombinant HSV-1 vector as described above, the nucleic acid sequence of the ICP34.5 gene comprises the sequence shown in SEQ ID NO: 1.
[0017] In some embodiments, the recombinant HSV-1 vector as described above, wherein the immune stimulatory factor such as IL-12 or the anti-immune checkpoint antibody such as anti-PD-1 antibody is of human or murine origin.
[0018] In some embodiments, the recombinant HSV-1 vector as described above, wherein the anti-immune checkpoint antibody such as anti-PD-1 antibody is a whole antibody, a single-chain antibody (scFv) or an antibody fragment.
[0019] In some embodiments, the recombinant HSV-1 vector as described above, wherein the nucleic acid sequence of the anti-PD-1 antibody comprises the sequence shown in SEQ ID NO: 2.
[0020] In some embodiments, the recombinant HSV-1 vector as described above, wherein the first exogenous nucleic acid sequence encoding IL-12 comprises a sequence obtained by concatenating SEQ ID NO: 3 and SEQ ID NO: 4 through IRES, preferably, the IRES sequence comprises the sequence shown in SEQ ID NO: 5.
[0021] In some embodiments, the recombinant HSV-1 vector as described above, wherein the vector further comprises a promoter sequence operably linked to the first exogenous nucleic acid sequence or the second exogenous nucleic acid sequence.
[0022] In some embodiments, the recombinant HSV-1 vector as described above, wherein the promoter is selected from at least one of CMV, SV40, EF1A, CBh and CAG promoters.
[0023] In some embodiments, the recombinant HSV-1 vector as described above, wherein the deletion of the ICP34.5 gene is a double copy gene deletion, the insertion of the first exogenous nucleic acid sequence encoding an immunostimulatory factor such as IL-12 is a double copy insertion or a single copy insertion, and the insertion of the second exogenous nucleic acid sequence encoding an anti-immune checkpoint antibody such as an anti-PD-1 antibody is a single copy insertion. In an alternative embodiment, the insertion of the first exogenous nucleic acid sequence encoding the immunostimulatory factor is a double copy insertion and the first exogenous nucleic acid sequence inserted at each insertion site is the same. In an alternative embodiment, the insertion of the first exogenous nucleic acid sequence encoding the immunostimulatory factor is a double copy insertion and the first exogenous nucleic acid sequence inserted at each insertion site is different.
[0024] Another aspect of the present invention relates to a pharmaceutical composition or kit comprising a therapeutically effective amount of the recombinant HSV-1 vector as described above, and one or more pharmaceutically acceptable carriers, diluents, buffers or excipients.
[0025] Another aspect of the present invention relates to the use of the recombinant HSV-1 vector as described above or the pharmaceutical composition or kit as described above in the preparation of a medicament for treating and / or preventing cancer.
[0026] In some embodiments, the cancer is selected from the group consisting of gallbladder cancer, bladder cancer, basal cell tumor, extrahepatic bile duct cancer, colorectal cancer, endometrial cancer, cervical cancer, esophageal cancer, breast cancer, Ewing sarcoma, prostate cancer, stomach cancer, glioma, Hodgkin lymphoma, laryngeal cancer, liver cancer, lung cancer, melanoma, mesothelioma, pancreatic cancer, kidney cancer, peripheral nerve tumors, skin and plexiform neurofibromas, leiomyomatoid tumors, fibroids, uterine fibroids, leiomyosarcomas, thyroid cancer, ascites, mesothelioma, salivary gland tumors, salivary gland mucoepidermoid carcinoma, salivary gland acinar cell carcinoma, gastrointestinal stromal tumors (GIST), tumors that cause fluid to accumulate in potential spaces of the body, pleural effusion, pericardial effusion, peritoneal effusion, giant cell tumor, pigmented villonodular synovitis (PVNS) , tenosynovial giant cell tumor (TGCT), and sarcoma; wherein, the liver cancer is preferably hepatocellular carcinoma (HCC), cholangiocellular carcinoma or mixed liver cancer; the lung cancer is preferably non-small cell carcinoma or small cell lung cancer; the peripheral nerve tumor is preferably malignant peripheral nerve sheath tumor (MPNST); the thyroid cancer is preferably selected from at least one of papillary thyroid carcinoma, anaplastic thyroid carcinoma, medullary thyroid carcinoma, follicular thyroid carcinoma and hurtle cell carcinoma; the ascites is preferably malignant ascites; the giant cell tumor is giant cell tumor of bone or giant cell tumor of tenosynovium; the salivary gland tumor is preferably salivary gland mucoepidermoid carcinoma or salivary gland acinar cell carcinoma; the laryngeal cancer is preferably laryngeal mucoepidermoid carcinoma; the colorectal cancer is preferably colon cancer or rectal cancer.
[0027] In some embodiments, the drug is administered locally or systemically, wherein local administration includes intratumoral injection, and systemic administration includes oral administration and intravascular injection, wherein intravascular injection is preferably intravenous injection.
[0028] Advantageous Effects of the Invention
[0029] The disclosed oncolytic virus has high expression level, good stability and high oncolytic activity. By modifying the viral structure, for example, by deleting the ICP34.5 gene in the HSV1-KOS strain genome and creatively introducing immune stimulatory factors and / or immune checkpoint antibodies such as PD-1 antibodies at the UL26 / 27 gene insertion site, a modified recombinant herpes simplex virus type I was obtained, which has a better tumor inhibition effect than before modification. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] FIG1 shows a schematic diagram of a portion of the genome structure of the original virus GHSV-UL46 (ATCC-VR-1544, GHSV-UL46).
[0031] FIG2 shows a schematic diagram of a partial structure of the genome of the recombinant herpes simplex virus vector HSV1-hIL12 (34.5KO)-αhPD1 (UL26 / 27) expressing immune stimulatory factors.
[0032] FIG3 shows the expression of the immunostimulatory factor IL12 in cells.
[0033] FIG4 shows the growth curves of different virus constructs on African green monkey kidney Vero cells.
[0034] FIG5 shows the growth curves of different constructs of the same viral vector with different insertion sites on African green monkey kidney Vero cells.
[0035] FIG6 shows the results of plaque assay 48 hours after virus infection.
[0036] FIG7 shows the killing effect of the recombinant herpes simplex virus vector HSV1-hIL12 (34.5KO) expressing the immunostimulatory factor IL12 and anti-hPD1 antibody on glioma cells U87-MG and laryngeal epidermoid carcinoma cells Hep-2.
[0037] FIG8 shows the killing effect of the recombinant herpes simplex virus vector HSV1-hIL12 (34.5KO) expressing the immunostimulatory factor IL12 and anti-hPD1 antibody on glioma cells LN229 and melanoma cells A375.
[0038] FIG9 shows the killing effect of the recombinant herpes simplex virus vector HSV1-hIL12 (34.5KO) expressing the immunostimulatory factor IL12 and anti-hPD1 antibody on melanoma cells SK-Mel-28 and bladder cancer cells 5637.
[0039] FIG10 shows the killing effect of the recombinant herpes simplex virus vector HSV1-hIL12 (34.5KO) expressing the immunostimulatory factor IL12 and anti-hPD1 antibody on non-small cell lung cancer cells A549 and hepatocellular carcinoma cells HepG2.
[0040] FIG11 shows the killing effect of the recombinant herpes simplex virus vector HSV1-hIL12 (34.5KO) expressing the immunostimulatory factor IL12 and anti-hPD1 antibody on prostate cancer cells LN-Cap, colorectal cancer cells HCT116, and breast cancer MCF-7.
[0041] Figure 12 shows the killing effects of HSV1-hIL12(34.5KO)-αhPD1(UL26 / 27) and other vectors (HSV1-hIL12(34.5KO)-αhPD1(UL3 / 4)) on non-small cell lung cancer cells A549, laryngeal epidermoid carcinoma cells Hep-2, and melanoma cells SK-Mel-28.
[0042] Figure 13 shows the killing effects of HSV1-hIL12(34.5KO)-αhPD1(UL26 / 27) and other vectors (HSV1-hIL12(34.5KO)-αhPD1(UL3 / 4)) on colorectal cancer cells HCT116, glioma cells LN229, and melanoma cells A375.
[0043] FIG. 14 shows the in vivo oncolytic activity of HSV1-hIL12(34.5KO)-αhPD1(UL26 / 27).
[0044] Detailed Description of the Invention
[0045] The present disclosure will be described in detail below based on the embodiments and in conjunction with the accompanying drawings. The above aspects of the present disclosure and other aspects of the present disclosure will be apparent from the detailed description below. The scope of the present disclosure is not limited to the following embodiments.
[0046] The antibodies disclosed herein are multispecific, humanized, single-chain, chimeric, synthetic, recombinant, hybrid, mutated, and grafted antibodies; the antibody format disclosed herein is a scFv spliced from an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH). The antibody light chain variable region (VL) and the antibody heavy chain variable region (VH) can be further subdivided into: a hypervariable region called a complementarity determining region (CDR), and an interspersed more conserved region called a framework region (FWR). The CDRs of the antibodies and antigen-binding fragments disclosed herein are defined or identified by Kabat numbering. In one embodiment, each VH and VL generally includes 3 CDRs and 4 FWRs arranged in the following order from amino terminus to carboxyl terminus: FWR1, CDR1, FWR2, CDR2, FWR3, CDR3, FWR4. The CDRs of the antibodies and antigen-binding fragments disclosed herein are defined or identified by Kabat numbering.
[0047] As used herein, the term "antibody fragment" or "antigen-binding fragment" is a portion of an antibody, such as F(ab')2, F(ab)2, Fab', Fab, Fv, scFv, and the like. Regardless of the structure, the antibody fragment binds to the same antigen recognized by the intact antibody. The term "antibody fragment" includes aptamers, spiegelmers, and diabodies. The term "antibody fragment" also includes any synthetic or genetically engineered protein that acts like an antibody by binding to a specific antigen to form a complex.
[0048] As used herein, "cancer" or "tumor," as used interchangeably herein, refers to a group of diseases that can be treated according to the present disclosure and involve abnormal or uncontrolled cell growth, which may invade or spread to other parts of the body. Not all tumors are cancerous; benign tumors do not spread to other parts of the body. Possible signs and symptoms include: new lumps, unusual bleeding, prolonged coughing, unexplained weight loss and changes in bowel movements, etc. There are more than 100 different known cancers that affect humans. The present disclosure is preferably applicable to solid tumors. Non-limiting examples of tumors or cancers include at least one of gallbladder cancer, bladder cancer, basal cell tumor, extrahepatic bile duct cancer, colorectal cancer, endometrial cancer, cervical cancer, esophageal cancer, breast cancer, Ewing's sarcoma, prostate cancer, stomach cancer, glioma, Hodgkin's lymphoma, laryngeal cancer, liver cancer, lung cancer, melanoma, mesothelioma, pancreatic cancer, kidney cancer, peripheral nerve tumors, skin and plexiform neurofibromas, leiomyomatoid tumors, fibroids, uterine fibroids, leiomyosarcomas, thyroid cancer, ascites, mesothelioma, salivary gland tumors, salivary gland mucoepidermoid carcinoma, salivary gland acinar cell carcinoma, gastrointestinal stromal tumors (GIST), tumors that cause fluid to accumulate in potential spaces of the body, pleural effusion, pericardial effusion, peritoneal effusion, giant cell tumor, pigmented villonodular synovitis (PVNS), tenosynovial giant cell tumor (TGCT), and sarcoma. Among them, the liver cancer can be hepatocellular carcinoma (HCC), cholangiocarcinoma or mixed liver cancer; the lung cancer can be non-small cell carcinoma or small cell lung cancer; the peripheral nerve tumor can be malignant peripheral nerve sheath tumor (MPNST); the thyroid cancer is selected from at least one of papillary thyroid carcinoma, anaplastic thyroid carcinoma, medullary thyroid carcinoma, follicular thyroid carcinoma and hurtle cell carcinoma; the ascites can be malignant ascites; the giant cell tumor can be giant cell tumor of bone or giant cell tumor of tendon sheath; the salivary gland tumor is preferably salivary gland mucoepidermoid carcinoma or salivary gland acinar cell carcinoma; the laryngeal cancer is preferably laryngeal mucoepidermoid carcinoma; the colorectal cancer is preferably colon cancer or rectal cancer.
[0049] As used herein, the term "treat" refers to both therapeutic treatment and prophylactic measures, the purpose of which is to prevent or slow (lessen) an undesirable physiological change or disorder, such as the progression of cancer. Beneficial or desired clinical results include, but are not limited to, relief of symptoms, reduction in the extent of the disease, stabilization (i.e., non-worsening) of the disease state, delay or slowing of disease progression, improvement or alleviation of the disease state, and disappearance of symptoms (whether partial or complete), whether detectable or undetectable. "Treatment" also means prolonging survival as compared to expected survival if not receiving treatment. Patients in need of treatment include those already suffering from the disease or condition, as well as those susceptible to the disease or condition, or those in whom the disease or condition is to be prevented.
[0050] "Subject" refers to any object, particularly a mammalian subject, for which diagnosis, prognosis, or treatment is desired. Mammalian subjects include humans or non-human animals such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows, and the like.
[0051] The term "administering" as used herein refers to the introduction of a drug or pharmaceutical composition into a subject.
[0052] The term "effective amount" refers to the minimum amount of a drug or pharmaceutical composition required to produce a specific physiological effect.
[0053] The term "vector" refers to a nucleic acid molecule capable of transferring or transporting another nucleic acid molecule. In some embodiments, the vector used in the present disclosure is a viral vector of herpes simplex type 1 virus.
[0054] Recombinant HSV-1 vector
[0055] On the one hand, the present disclosure provides a recombinant HSV-1 vector comprising a modified HSV-1 genome, wherein the modification comprises a deletion of the ICP34.5 gene in the HSV1-KOS strain genome, the vector comprising: (a) a first exogenous nucleic acid sequence encoding an immunostimulatory factor such as IL-12; and (b) a second exogenous nucleic acid sequence encoding an anti-immune checkpoint such as a PD-1 antibody; wherein the second exogenous nucleic acid sequence encoding an anti-immune checkpoint such as a PD-1 antibody is inserted between the UL26 and UL27 genes of the HSV1-KOS strain genome, and the insertion of the first exogenous nucleic acid sequence or the second exogenous nucleic acid sequence does not interfere with the expression of HSV-1. The first exogenous nucleic acid sequence encoding an immunostimulatory factor such as IL-12 is inserted into the region where the ICP34.5 gene is deleted in the HSV1-KOS strain genome or between the UL3 and UL4 genes of the HSV1-KOS strain genome. The deletion of the ICP34.5 gene is a deletion of two copies of the ICP34.5 gene or a deletion of amino acids 1-146 of the N-terminal sequence in the ICP34.5 gene. The nucleic acid sequence of the ICP34.5 gene includes or is SEQ ID NO: 1. It should be understood by those skilled in the art that the immunostimulatory factor may preferably be selected from at least one of GM-CSF, IL-2, IL-12, IL-15, IL-24 and IL-27. The immune checkpoint may preferably be selected from at least one of PD-1, CTLA-4, VISTA, LAG-3, TIGIT and PD-L1. The vector further includes a promoter sequence or other elements operably linked to the first exogenous nucleic acid sequence or the second exogenous nucleic acid sequence. Preferably, the deletion of the ICP34.5 gene is a deletion of a double copy gene, the insertion of the first exogenous nucleic acid sequence encoding the immunostimulatory factor is double copy or single copy, and the insertion of the second exogenous nucleic acid sequence encoding the anti-immune checkpoint antibody is single copy.
[0056] HSV1-KOS strain was derived from ATCC-VR-1544, GHSV-UL46.
[0057] Pharmaceutical composition
[0058] Oncolytic viruses can be prepared in suitable pharmaceutically acceptable carriers or excipients. Under normal storage and use conditions, these preparations contain preservatives to prevent the growth of microorganisms. Pharmaceutical forms suitable for injection include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the preparation must be sterile and must be fluid for easy injection. It must be stable under production and storage conditions and must prevent contamination by microorganisms such as bacteria and fungi. As used herein, "pharmaceutically acceptable carriers" include any and all solvents, dispersion media, carriers, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, etc. Media and agents for pharmaceutically active substances are well known in the art. In addition to any conventional media or agents that are incompatible with the active ingredient, it is expected that other media or agents can be used in the therapeutic composition. Supplementary active ingredients can also be incorporated into the composition. "Pharmaceutically acceptable" refers to molecular entities and components that do not produce allergic or similar adverse reactions when administered to humans. The preparation of aqueous compositions containing proteins as active ingredients is well understood in the art. Typically, such compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for dissolution or suspension in liquid prior to injection can also be prepared. Example
[0059] The present disclosure is further described below with reference to the following examples, but these examples are not intended to limit the scope of the present disclosure. Experimental methods in the examples of the present disclosure where specific conditions are not specified generally follow conventional conditions. Reagents where the specific sources are not specified are conventional reagents purchased from the market.
[0060] The experimental materials used in the following examples are shown in Tables 1 and 2:
[0061] Table 1. Key Reagents
[0062] Table 2. Key instruments
[0063] Example 1: Genomic Structure of the Recombinant Herpes Simplex Virus Vector HSV1-hIL12 (34.5KO)-αhPD1 (UL26 / 27) Expressing Immunostimulatory Factors
[0064] As shown in Figure 2, in the HSV1-hIL12(34.5KO)-αhPD1(UL26 / 27) virus, the neurotoxic protein ICP34.5 (SEQ ID NO: 1) was replaced with hIL12 and the hPD-1 single-chain antibody gene (SEQ ID NO: 2) was inserted between the viral genome UL26 / 27, where hIL12 was composed of IL12B (SEQ ID NO: 5) and IL12A (SEQ ID NO: 6) connected in series via an internal ribosome entry site sequence (IRES, SEQ ID NO: 7).
[0065] The construction of the recombinant virus is achieved through Red recombination based on conventional bacterial artificial chromosomes (BAC) or accessible means such as gene editing technology such as CRISPR / Cas9. The specific construction method is: based on the laboratory-passaged virus HSV1-KOS strain (ATCC-VR-1544, GHSV-UL46, schematic diagram see Figure 1), the neurotoxic protein ICP34.5 (SEQ ID NO: 1) is knocked out using the gene editing technology CRISPR / Cas9, and the ICP34.5 gene is deleted and replaced with the IL12 gene using a two-step method. First, the ICP34.5 gene is replaced with the GFP gene, and fluorescent cell lesions are selected; then the GFP gene is replaced with IL12, and non-fluorescent cell lesions are selected. This two-step method greatly improves work efficiency. The specific operations are as follows:
[0066] 1) Construct a donor plasmid containing the GFP gene and a sgRNA plasmid targeting the ICP34.5 gene (SEQ ID NO: 8). Co-transfect Vero cells with the GFP donor plasmid and the sgRNA plasmid. Simultaneously, infect the Vero cells with the HSV1-KOS virus and observe cytopathic effects. If the ICP34.5 gene is successfully replaced with the GFP gene, green fluorescent lesions will be observed. Select the green fluorescent lesions and purify the HSV1 recombinant virus (HSV1-ICP34.5KO-GFP) in which the ICP34.5 gene is successfully replaced with the GFP gene by a plaque assay.
[0067] 2) Construct a donor plasmid containing the IL12 gene, and at the same time construct an sgRNA plasmid targeting the GFP gene (SEQ ID NO: 11). The donor plasmid and sgRNA plasmid are co-transfected into Vero cells and the HSV1-ICP34.5KO-GFP recombinant virus is simultaneously infected into Vero cells. Subsequent observation of cytopathic effects indicates that if the GFP gene is successfully replaced with the IL12 gene, cytopathic effects without green fluorescence will appear. Cells without green fluorescent cytopathic effects are picked and purified by plaque assay to obtain HSV1-hIL12 (34.5KO) virus; wherein hIL12 is composed of IL12B (SEQ ID NO: 5) and IL12A (SEQ ID NO: 6) connected in series through an internal ribosome entry site sequence (IRES, SEQ ID NO: 7).
[0068] 3) The hPD-1 single-chain antibody gene was inserted into the viral genome between UL26 / 27 (the gRNA sequence of UL26 / 27 is SEQ ID NO: 9) using the CRISPR / Cas9 two-step method to obtain the HSV1-hIL12 (34.5KO)-αhPD1 (UL26 / 27) viral vector; wherein hPD1 is composed of Heavy chain V (SEQ ID NO: 2) and Light chain V (SEQ ID NO: 3) connected in series via linker (G4S) 3 (SEQ ID NO: 5).
[0069] 4) The hPD-1 single-chain antibody gene was inserted into the viral genome between UL3 / 4 (the gRNA sequence of UL3 / 4 is SEQ ID NO: 10) using the CRISPR / Cas9 two-step method to obtain the HSV1-hIL12 (34.5KO)-αhPD1 (UL3 / 4) viral vector; wherein hPD1 is composed of Heavy chain V (SEQ ID NO: 2) and Light chain V (SEQ ID NO: 3) connected in series via linker (G4S) 3 (SEQ ID NO: 5).
[0070] In addition, a mouse version of the recombinant herpes simplex virus vector HSV1-mIL12(34.5KO)-αmPD1(UL26 / 27) was constructed, in which the mouse cytokine IL-12 and mouse PD-1 single-chain antibody genes were inserted, and the target gene can be effectively expressed.
[0071] Table 3. Sequence information
[0072] Example 2: Detection of IL-12 expression in cells infected with HSV1-hIL12(34.5KO)-αhPD1(UL26 / 27) or HSV1-mIL12(34.5KO)-αmPD1(UL26 / 27)
[0073] Vero cells were seeded at a density of 10,000 cells / well in 96-well plates. The next day, before infection, 50 μL of the original culture medium was aspirated and the virus was diluted to 1e+6 PFU / mL. Recombinant herpes simplex virus vectors expressing the immunostimulatory molecule IL-12, HSV1-hIL12 (34.5 KO) or HSV1-mIL12 (34.5 KO), and wild-type virus (wtHSV1), were then infected at an MOI of 3. Two hours after infection, the supernatant was aspirated, the cells were washed once with 100 μL of PBS, and the cells were cultured in 100 μL of DMEM medium. After 48 hours, the infected culture supernatant and cell lysate were harvested and assayed using the Human IL-12p70 Quantikine HS ELISA Kit (R&D-HS120) or the Mouse IL-12p70 ELISA Kit (R&D-M1270) according to the kit instructions. As shown in Figure 3, the standard curve calculation shows that the concentration of IL-12 in the culture supernatant is higher than that in the cell lysate. The IL12 concentration in the culture supernatant is 2-5 ng / mL, and the IL12 concentration in the cell lysate is about 1 ng / mL. However, the wild-type virus does not express IL-12 after infection.
[0074] Example 3: Proliferation characteristics of HSV1-hIL12 (34.5KO)-αhPD1 (UL26 / 27) in African green monkey kidney cells (Vero)
[0075] The viruses are grouped as follows:
[0076] 1) HSV1-KOS (wt) is wild-type herpes simplex virus type 1;
[0077] 2) HSV1-34.5KO is a herpes simplex virus type with the ICP34.5 gene knocked out;
[0078] 3) HSV1-hIL12 (34.5KO) is a herpes simplex virus with the ICP34.5 gene replaced by hIL12;
[0079] 4) HSV1-hIL12(34.5KO)-αhPD1(UL26 / 27) is a herpes simplex virus type 1 in which the ICP34.5 gene is replaced with hIL12 and the hPD-1 single-chain antibody gene is inserted between UL26 / 27 of the viral genome.
[0080] Vero cells were seeded at a density of 10,000 / well in 96-well plates. The next day, four different virus groups (HSV1-KOS (wt), HSV1-34.5KO, HSV1-hIL12 (34.5KO), and HSV1-hIL12 (34.5KO)-αhPD1 (UL26 / 27)) were diluted in cell culture medium. Before infection, 50 μL of the original culture medium was aspirated, and the viruses were diluted to 1e+6 PFU / mL and infected into Vero cells at an MOI of 0.1. Two hours after infection, the supernatant was aspirated, the cells were washed once with 100 μL of PBS, and 100 μL of DMEM medium was added for further culture. The virus-infected culture supernatant and cell lysate were harvested 24, 48, 72, and 96 hours after infection. The viruses harvested at different time points were titered on Vero cells as follows.
[0081] Vero cells were seeded at a density of 500,000 per well in 6-well plates. The next day, the harvested viruses were diluted 10-fold in serum-free medium. 1 mL of each diluted virus was then added to the 6-well plates and infected for 2 hours at 37°C. During infection, agarose was heated on an induction cooktop and 3.3% FBS-containing DMEM was dissolved overnight. Both solutions were then placed in a 37°C, 5% CO2 incubator until ready for use. Five minutes before infection, 1 volume of 2.5% low-melting-point agarose solution was mixed with 1.5 volumes of 3.3% FBS-containing DMEM. After infection, the infection solution was discarded and 2 mL of the agarose mixture was added to each well. The plates were then incubated in a biosafety cabinet for 10-30 minutes to allow the agarose to solidify. Finally, the plates were incubated at 37°C, 5% CO2 for 72 hours before plaque detection. Viral titers at each time point were determined by counting plaques, and viral growth curves were plotted to assess viral proliferation characteristics. As shown in FIG4 , the proliferation ability of the recombinant virus HSV1-hIL12(34.5KO)-αhPD1(UL26 / 27) was comparable to that of the wild-type virus.
[0082] Example 4: Proliferation characteristics of different constructs of the same viral vector with different insertion sites in African green monkey kidney cells (Vero)
[0083] The insertion sites are grouped as follows:
[0084] A) HSV1-KOS (wt) is wild-type herpes simplex virus type 1,
[0085] B) HSV1-hIL12(34.5KO)-αhPD1(UL26 / 27) is a herpes simplex virus type 1 in which the ICP34.5 gene is replaced with hIL12 and the hPD-1 single-chain antibody gene is inserted between the UL26 / 27 region of the viral genome.
[0086] C) HSV1-hIL12(34.5KO)-αhPD1(UL3 / 4) is a herpes simplex virus type 1 in which the ICP34.5 gene is replaced by hIL12 and the hPD-1 single-chain antibody gene is inserted between UL3 / 4 of the viral genome.
[0087] Vero cells were seeded into 96-well plates at a density of 10,000 / well. The next day, three different viruses (HSV1-KOS (wt), HSV1-hIL12 (34.5KO)-αhPD1 (UL26 / 27), and HSV1-hIL12 (34.5KO)-αhPD1 (UL3 / 4)) were diluted in cell culture medium. Before infection, 50 μL of the original culture medium was aspirated and the viruses were diluted to 1e+6 PFU / mL. Vero cells were infected at an MOI of 0.1. After 2 hours of infection, the supernatant was aspirated and the cells were washed once with 100 μL PBS and continued to be cultured with 100 μL DMEM medium. The virus-infected culture supernatant and cell lysate were harvested 24 hours, 48 hours, 72 hours, and 96 hours after virus infection. The harvested viruses were also titered on Vero cells.
[0088] Vero cells were seeded into 6-well plates at a density of 500,000 cells / well. The next day, the harvested virus was diluted 10-fold in serum-free medium. 1 mL of virus at each dilution was then added to the 6-well plates and infected for 2 hours at 37°C. During infection, agarose was heated on an induction cooktop while 3.3% FBS-containing DMEM was dissolved overnight. Both solutions were then placed in a 37°C, 5% CO2 incubator until ready for use. Five minutes before infection, 1 volume of 2.5% low-melting-point agarose solution was mixed with 1.5 volumes of 3.3% FBS-containing DMEM overnight. After infection, the infection solution was discarded and 2 mL of the agarose mixture was added to each well. The plates were then incubated in a biosafety cabinet for 10-30 minutes to allow the agarose to solidify. Finally, the plates were incubated at 37°C, 5% CO2 for 72 hours before plaque detection. Virus titers at each time point were calculated by counting plaques, and viral growth curves were plotted to assess viral proliferation characteristics. Figure 5 shows the viral growth curve, showing that the proliferation capacity of HSV1-hIL12(34.5KO)-αhPD1(UL26 / 27) was significantly enhanced compared to HSV1-hIL12(34.5KO)-αhPD1(UL3 / 4). Figure 6 shows the results of a plaque assay 48 hours after viral infection, showing that the plaques formed after infection with hIL12(34.5KO)-αhPD1(UL26 / 27) were larger and more numerous than those formed with HSV1-hIL12(34.5KO)-αhPD1(UL3 / 4).
[0089] Example 5: In vitro oncolytic activity of HSV1-hIL12 (34.5KO)-αhPD1 (UL26 / 27) on different tumor cells
[0090] Eleven different tumor cells were inoculated into 96-well plates. The next day, 50 μL of the original culture medium was aspirated before infection, and the virus was diluted to 1e+6 PFU / mL. The four different viruses in Example 3 were used to infect different tumor cells at different multiplicity of infection MOI = 0.03 / 0.3 / 3. Specific cell types and culture information are shown in Table 4. After 2 hours of infection, the supernatant was aspirated and discarded, and the cells were washed once with 100 μL PBS. 100 μL DMEM culture medium was added and cultured continuously. CCK-8 reagent was added every 24 hours and incubated at 37°C for 2 hours. The absorbance of the culture solution was detected at 450 nm and 630 nm. The viability of the tumor cells infected with the virus was calculated by reading the absorbance of the culture solution. As shown in Figures 7-11, by plotting the cell viability curves at different time points of infected cells, it can be seen that the virus HSV1-hIL12(34.5KO)-αhPD1(UL26 / 27) can significantly kill a variety of tumor cells. When the multiplicity of infection is 0.03, HSV1-hIL12(34.5KO)-αhPD1(UL26 / 27) can completely kill melanoma cells SK-MEL-28, liver cancer cells HepG2 and prostate cancer cells LN-Cap after 96 hours of infection.
[0091] Example 6: Comparison of HSV1-hIL12 (34.5KO)-αhPD1 (UL26 / 27) with other vectors
[0092] According to Example 1, HSV1-hIL12 (34.5KO) -αhPD1 (UL26 / 27) was prepared, and the in vitro oncolytic activity was detected under the experimental conditions of Example 5. The recombinant virus disclosed herein knocked in two anti-tumor immune regulatory factors to enhance the body's anti-tumor cell immunity, and showed a good killing effect in in vitro killing experiments on various tumor cells. Compared with the existing herpes simplex oncolytic viruses on the market, such as T-VEC or ΔG47 (Delytact), under the premise of ensuring the same safety (knocking out the neurovirulence factor ICP34.5 gene), the recombinant virus disclosed herein has exogenous immune regulatory genes inserted at multiple sites.Many recombinant herpes simplex oncolytics reported so far have inserted exogenous genes between UL3 / 4 and have shown excellent tumor killing effects (Menotti, Laura, and Elisa Avitabile. "Herpes simplex virus oncolytic immunovirotherapy: the blossoming branch of multimodal therapy." International Journal of Molecular Sciences 21.21(2020):8310. Kennedy, Edward M., et al. "Design of an interferon-resistant oncolytic HSV-1 incorporating redundant safety modalities for improved tolerability." Molecular Therapy-Oncolytics 18(2020):476-490. Thomas S, Kuncheria L, Roulstone V, et al. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1[J]. Journal for immunotherapy of cancer, 2019, 7(1):1-17. Abstract 1455: Design of ONCR-177 base vector, a next-generation oncolytic herpes simplex virus type-1, optimized for robust oncolysis, transgene expression and tumor-selective replication. The recombinant virus disclosed herein creatively inserts an exogenous immune regulatory gene between UL26 / 27 and can achieve a more optimal tumor-killing effect.
[0093] Therefore, CRISPR / Cas9 technology was used to construct a recombinant HSV1 oncolytic virus, HSV1-hIL12 (34.5KO) -αhPD1 (UL3 / 4), in which the exogenous gene αhPD1 was inserted into the UL3 / 4 site. HSV1-hIL12 (34.5KO) -αhPD1 (UL3 / 4) is a type of herpes simplex virus in which the 34.5 gene is replaced with hIL12 and the hPD-1 single-chain antibody gene is inserted between the UL3 / 4 of the viral genome. Compared with the preparation of HSV1-hIL12 (34.5KO) -αhPD1 (UL26 / 27) according to Example 1, the difference is that the site of hPD1 insertion is different. In HSV1-hIL12 (34.5KO) -αhPD1 (UL3 / 4), hPD1 is inserted between the UL3 / 4 of the genome. A variety of human tumor cells (A375, LN229, A549, SK-Mel-28, Hep2, and HCT116) were selected and seeded into 96-well plates at appropriate cell densities (see Table 4). Viral infection experiments were performed 18-24 hours later. Before infection, 50 μL of the original culture medium was aspirated and the recombinant viruses, HSV1-hIL12(34.5KO)-αhPD1(UL3 / 4) and HSV1-hIL12(34.5KO)-αhPD1(UL26 / 27), were diluted to a titer of 1e+06 PFU / mL and infected with the respective tumor cells at an MOI of 0.03 / 0.3 / 3. Two hours after infection, the supernatant was aspirated and the cells were washed once with 100 μL of PBS and continued to be cultured in 100 μL of DMEM medium. CCK-8 reagent was added after 24, 48, 72, and 96 hours of culture, and the cells were incubated at 37°C for 2 hours. The absorbance of the culture medium was detected at 450 nm and 630 nm. The viability of the tumor cells infected by the virus was calculated by reading the absorbance value of the culture medium. The cell viability curves of the infected cells at different time points were plotted to show the killing activity of the virus on the corresponding tumor cells, and the killing activity of the various oncolytic viruses constructed on different tumor cells was compared. As shown in Figures 12-13, compared with HSV1-hIL12 (34.5KO) -αhPD1 (UL3 / 4), the recombinant virus disclosed herein showed better oncolytic killing effects in in vitro killing experiments of various tumor cells.
[0094] Table 4. Cell culture information
[0095] Example 7: Evaluation of in vivo oncolytic activity of HSV1-hIL12 (34.5KO)-αhPD1 (UL26 / 27)
[0096] SK-Mel-28 tumor cells were cultured in a 37°C, 5% CO2 incubator using complete cell culture medium (see Table 4). When the cell count reached the required level for establishing a mouse tumor model, the cells were digested with 0.05% trypsin and washed with PBS to obtain a cell suspension containing 50% Matrigel (cell density: 8e+7 cells / mL).
[0097] Take 0.1mL of SK-Mel-28 cell suspension and inoculate it into the subcutaneous tissue of 4-6 week old nude mice to establish human melanoma cell line subcutaneous tumor model. 3 At 4 hr, the mice were divided into groups and started to receive treatment. The treatment schedule is shown in Table 5.
[0098] Tumor volume was measured twice a week using an electronic vernier caliper. Tumor volume was calculated using the formula: V (volume) = (L × (W) 2 ) / 2; L represents the tumor length, and W represents the tumor width.
[0099] As shown in FIG14 , the recombinant virus disclosed herein still has a significant tumor inhibitory effect in an in vivo model experiment of human melanoma tumor cells SK-Mel-28 at a low dose of 8e+4 PFU / mouse, showing a good oncolytic killing effect.
[0100] Table 5. Treatment options
[0101] Example 8: Recombinant herpes simplex virus vector expressing immune stimulatory factors and its biological function
[0102] Based on the viral HSV1-KOS strain (ATCC-VR-1544, GHSV-UL46), referring to the method of Example 1, the neurotoxic protein ICP34.5 (SEQ ID NO: 1) was knocked out using the gene editing technology CRISPR / Cas9, and the ICP34.5 gene was deleted and replaced with the IL-2 sequence (gene sequence Genbank Accession No.: NM_000586.4; amino acid sequence Genbank Accession No.: NP_000577.2) using a two-step method. The CTLA-4 gene (gene sequence Genbank Accession No.: NM_001037631.3; amino acid sequence Genbank Accession No.: NP_001032720.1) was inserted between the viral genome UL26 / 27 to construct a recombinant herpes simplex virus vector expressing immune stimulatory factors.
[0103] Based on the viral HSV1-KOS strain (ATCC-VR-1544, GHSV-UL46), referring to the method of Example 1, the neurotoxic protein ICP34.5 (SEQ ID NO: 1) was knocked out using the gene editing technology CRISPR / Cas9, and the ICP34.5 gene was deleted and replaced with the IL-2 sequence (gene sequence Genbank Accession No.: NM_000586.4; amino acid sequence Genbank Accession No.: NP_000577.2) using a two-step method. The anti-PD-L1 antibody gene (VH amino acid sequence DrugBank Accession Number: DB11595; VL amino acid sequence DrugBank Accession Number: DB11595) was inserted between the viral genome UL26 / 27 to construct a recombinant herpes simplex virus vector expressing an immune stimulatory factor.
[0104] Based on the viral HSV1-KOS strain (ATCC-VR-1544, GHSV-UL46), referring to the method of Example 1, the neurotoxic protein ICP34.5 (SEQ ID NO: 1) was knocked out using the gene editing technology CRISPR / Cas9, and the ICP34.5 gene was deleted and replaced with the GM-CSF sequence (gene sequence Genbank Accession No.: NM_000758.4; amino acid sequence Genbank Accession No.: NP_000749.2) using a two-step method. The CTLA-4 gene (gene sequence Genbank Accession No.: NM_001037631.3; amino acid sequence Genbank Accession No.: NP_001032720.1) was inserted between the viral genome UL26 / 27 to construct a recombinant herpes simplex virus vector expressing immune stimulatory factors.
[0105] Based on the viral HSV1-KOS strain (ATCC-VR-1544, GHSV-UL46), referring to the method of Example 1, the neurotoxic protein ICP34.5 (SEQ ID NO: 1) was knocked out using the gene editing technology CRISPR / Cas9, and the ICP34.5 gene was deleted and replaced with the GM-CSF sequence (gene sequence Genbank Accession No.: NM_000758.4; amino acid sequence Genbank Accession No.: NP_000749.2) using a two-step method. The anti-PD-L1 antibody gene (VH amino acid sequence DrugBank Accession Number: DB11595; VL amino acid sequence DrugBank Accession Number: DB11595) was inserted between the viral genome UL26 / 27 to construct a recombinant herpes simplex virus vector expressing an immunostimulatory factor.
[0106] Based on the viral HSV1-KOS strain (ATCC-VR-1544, GHSV-UL46), referring to the method of Example 1, the neurotoxic protein ICP34.5 (SEQ ID NO: 1) was knocked out using the gene editing technology CRISPR / Cas9, and the ICP34.5 gene was deleted and replaced with the IL-15 sequence (gene sequence Genbank Accession No.: NR_037840.3; amino acid sequence Genbank Accession No.: NP_000576.1) using a two-step method. The CTLA-4 gene (gene sequence Genbank Accession No.: NM_001037631.3; amino acid sequence Genbank Accession No.: NP_001032720.1) was inserted between the viral genome UL26 / 27 to construct a recombinant herpes simplex virus vector expressing immune stimulatory factors.
[0107] Based on the viral HSV1-KOS strain (ATCC-VR-1544, GHSV-UL46), referring to the method of Example 1, the neurotoxic protein ICP34.5 (SEQ ID NO: 1) was knocked out using the gene editing technology CRISPR / Cas9, and the ICP34.5 gene was deleted and replaced with the IL-15 sequence (gene sequence Genbank Accession No.: NR_037840.3; amino acid sequence Genbank Accession No.: NP_000576.1) using a two-step method. The anti-PD-L1 antibody gene (VH amino acid sequence DrugBank Accession Number: DB11595; VL amino acid sequence DrugBank Accession Number: DB11595) was inserted between the viral genome UL26 / 27 to construct a recombinant herpes simplex virus vector expressing an immune stimulatory factor.
[0108] The resulting constructs were evaluated using the biological activity assays described in Examples 2-7 for cytokine expression after infection, proliferation characteristics of Vero cells, and in vitro and in vivo oncolytic activity against various tumor cells. The results demonstrated that these viral vectors exhibited robust oncolytic activity.
Claims
1. A recombinant HSV-1 vector comprising a modified HSV-1 genome, characterized in that The modification includes the deletion of the ICP34.5 gene in the HSV1-KOS strain genome, and the recombinant HSV-1 vector includes: (a) a first exogenous nucleic acid sequence encoding an immunostimulatory factor; and (b) a second exogenous nucleic acid sequence encoding an anti-immune checkpoint antibody; wherein the insertion site of the first exogenous nucleic acid sequence or the second exogenous nucleic acid sequence is between the UL26 and UL27 genes of the HSV1-KOS strain genome, and the insertion of the first exogenous nucleic acid sequence or the second exogenous nucleic acid sequence does not interfere with the expression of HSV-1.
2. The recombinant HSV-1 vector according to claim 1, characterized in that The insertion site of the first exogenous nucleic acid sequence encoding the immunostimulatory factor is in the region where the ICP34.5 gene is deleted in the HSV1-KOS strain genome or between the UL3 and UL4 genes of the HSV1-KOS strain genome, and the insertion site of the second exogenous nucleic acid sequence encoding the anti-immune checkpoint antibody is between the UL26 and UL27 genes of the HSV1-KOS strain genome; or The insertion site of the first exogenous nucleic acid sequence encoding the immunostimulatory factor is between the UL26 and UL27 genes of the HSV1-KOS strain genome, and the insertion site of the second exogenous nucleic acid sequence encoding the anti-immune checkpoint antibody is in the region where the ICP34.5 gene is deleted in the HSV1-KOS strain genome or between the UL3 and UL4 genes of the HSV1-KOS strain genome.
3. The recombinant HSV-1 vector according to claim 1 or 2, characterized in that The immunostimulatory factor is selected from at least one of GM-CSF, IL-2, IL-12, IL-15, IL-24 and IL-27; and the immune checkpoint is selected from at least one of PD-1, CTLA-4, VISTA, LAG-3, TIGIT and PD-L1.
4. The recombinant HSV-1 vector according to any one of claims 1 to 3, characterized in that The HSV-1 vector comprises: (a) a first exogenous nucleic acid sequence encoding IL-12; and (b) a second exogenous nucleic acid sequence encoding an anti-PD-1 antibody.
5. The recombinant HSV-1 vector according to any one of claims 1 to 4, characterized in that The ICP34.5 gene deletion is a double copy deletion of the ICP34.5 gene or a deletion of amino acids 1-146 of the N-terminal sequence of the ICP34.5 gene.
6. The recombinant HSV-1 vector according to any one of claims 1 to 5, characterized in that The nucleic acid sequence of the ICP34.5 gene comprises the sequence shown in SEQ ID NO:
1.
7. The recombinant HSV-1 vector according to any one of claims 1 to 6, characterized in that The immune stimulatory factor or anti-immune checkpoint antibody is selected from the group consisting of murine, human, primate and chimeric factors or antibodies, preferably selected from human factors or antibodies.
8. The recombinant HSV-1 vector according to any one of claims 1 to 7, characterized in that The anti-immune checkpoint antibody is a complete antibody, a single-chain antibody or an antibody fragment.
9. The recombinant HSV-1 vector according to claim 3, characterized in that The nucleic acid sequence of the anti-PD-1 antibody comprises the sequence shown in SEQ ID NO:
2.
10. The recombinant HSV-1 vector according to claim 3, characterized in that The first exogenous nucleic acid sequence encoding IL-12 comprises a sequence obtained by concatenating SEQ ID NO: 3 and SEQ ID NO: 4 via an IRES. Preferably, the IRES sequence comprises a sequence as shown in SEQ ID NO:
5.
11. The recombinant HSV-1 vector according to any one of claims 1 to 10, characterized in that The HSV-1 vector further comprises a promoter sequence operably linked to the first exogenous nucleic acid sequence or the second exogenous nucleic acid sequence.
12. The recombinant HSV-1 vector according to claim 11, characterized in that The promoter is selected from at least one of CMV, SV40, EF1A, CBh and CAG promoters.
13. The recombinant HSV-1 vector according to any one of claims 1 to 12, characterized in that The deletion of the ICP34.5 gene is a double copy deletion of the ICP34.5 gene, the insertion of the first exogenous nucleic acid sequence encoding the immunostimulatory factor is a double copy insertion or a single copy insertion, and the insertion of the second exogenous nucleic acid sequence encoding the anti-immune checkpoint antibody is a single copy insertion.
14. A pharmaceutical composition or kit, characterized in that The pharmaceutical composition or kit comprises a therapeutically effective amount of the recombinant HSV-1 vector according to any one of claims 1 to 13, and one or more pharmaceutically acceptable carriers, diluents, buffers or excipients.
15. Use of the recombinant HSV-1 vector according to any one of claims 1 to 13 or the pharmaceutical composition or kit according to claim 14 in the preparation of a medicament for treating and / or preventing cancer.
16. The use according to claim 15, characterized in that The cancer is selected from the group consisting of gallbladder cancer, bladder cancer, basal cell tumor, extrahepatic bile duct cancer, colorectal cancer, endometrial cancer, cervical cancer, esophageal cancer, breast cancer, Ewing's sarcoma, prostate cancer, stomach cancer, glioma, Hodgkin's lymphoma, laryngeal cancer, liver cancer, lung cancer, melanoma, mesothelioma, pancreatic cancer, kidney cancer, peripheral nerve tumors, skin and plexiform neurofibromas, leiomyomatoid tumors, fibroids, uterine fibroids, leiomyosarcomas, thyroid cancer, ascites, mesothelioma, salivary gland tumors, salivary gland mucoepidermoid carcinoma, salivary gland acinar cell carcinoma, gastrointestinal stromal tumors (GIST), tumors that cause fluid to accumulate in potential spaces of the body, pleural effusion, pericardial effusion, peritoneal effusion, giant cell tumor, pigmented villonodular synovitis (PVNS), tenosynovial giant cell tumors, At least one of thyroid carcinoma (TGCT) and sarcoma, wherein the liver cancer is preferably hepatocellular carcinoma (HCC), cholangiocarcinoma or mixed liver cancer; the lung cancer is preferably non-small cell carcinoma or small cell lung cancer; the peripheral nerve tumor is preferably malignant peripheral nerve sheath tumor (MPNST); the thyroid cancer is preferably selected from at least one of papillary thyroid carcinoma, anaplastic thyroid carcinoma, medullary thyroid carcinoma, follicular thyroid carcinoma and hurtle cell carcinoma; the ascites is preferably malignant ascites; the giant cell tumor is giant cell tumor of bone or giant cell tumor of tendon sheath; the salivary gland tumor is preferably salivary gland mucoepidermoid carcinoma or salivary gland acinar cell carcinoma; the laryngeal cancer is preferably laryngeal mucoepidermoid carcinoma; the colorectal cancer is preferably colon cancer or rectal cancer.
17. The use according to claim 15, characterized in that The drug is administered locally or systemically, wherein the local administration includes intratumoral injection, and the systemic administration includes oral administration and intravascular injection, wherein the intravascular injection is preferably intravenous injection.
